Adaptation of NS cells growth and differentiation to high-throughput screening-compatible plates by Garavaglia, Alessia et al.
METHODOLOGY ARTICLE Open Access
Adaptation of NS cells growth and differentiation
to high-throughput screening-compatible plates
Alessia Garavaglia
1, Alessia Moiana
2, Stefano Camnasio
1, Daniele Bolognini
1, Roberto Papait
1, Dorotea Rigamonti
1*,
Elena Cattaneo
2*
Abstract
Background: There is an urgent need of neuronal cell models to be applied to high-throughput screening
settings while recapitulating physiological and/or pathological events occurring in the Central Nervous System
(CNS). Stem cells offer a great opportunity in this direction since their self renewal capacity allows for large scale
expansion. Protocols for directed differentiation also promise to generate populations of biochemically
homogenous neuronal progenies. NS (Neural Stem) cells are a novel population of stem cells that undergo
symmetric cell division in monolayer and chemically defined media, while remaining highly neurogenic.
Results: We report the full adaptation of the NS cell systems for their growth and neuronal differentiation to 96-
and 384-well microplates. This optimized system has also been exploited in homogeneous and high-content
assays.
Conclusions: Our results show that these mouse NS cells may be suitable for a series of applications in high-
throughput format.
Background
Highly-informative automated assays that monitor cell
morphology, proliferation, death, motility and differentia-
tion offer, nowadays, a great opportunity for the discovery
of new gene functions, the study of molecular networks,
the identification and validation of disease-relevant drug
targets as well as the selection of pharmacologically active
compounds. These assays are crucial for the obtainment
of rapid, reliable and reproducible results. However, biolo-
gical systems inevitably bring along some disadvantages
with respect to a pure biochemical assay. Therefore one
aim is to optimize the number and quality of the informa-
tion gained from the selected cell model. Generally, the
closest the cells employed recapitulate their in vivo coun-
terparts, the more reliable the obtained data are for a
given situation or pathology.
Cells for drug discovery research are typically obtained
from primary tissues, genetically transformed or immor-
talized tumor cells [1]. More recent stem cell
technologies may offer a number of important advan-
tages, including the availability of an indefinite and
reproducible source of relevant cells, the possibility to
grow them close to biological and biochemical homoge-
neity and the capability to direct their differentiation
toward the various mature cell types present in the body
organism, including neurons. These benefits are to be
taken into particular consideration especially when deal-
ing with central nervous system (CNS) cells and related
disorders, where the need for relevant cellular models is
justified also by the difficulty in obtaining the relevant
cells from fresh tissue. Moreover, improved in vitro
models based on physiologically relevant neural cells
may also presumably result in more cost-effective assays.
Furthermore, the employment of different neural stem
cell systems and of their functionally mature neuronal
progeny in screening assays may also open the possibi-
lity of a broader cell system biology approach, able to
cast a much wider net than target-by-target approaches,
increasing the possibility to identify pharmacologically
active agents. In fact, many potential drugs do not bind
to a single specific target but exert their effect through
pathway mediated actions and these can be identified
only by complex biological screens [2,3].
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by the neurospheres culture which are identified as
floating multicellular clusters that proliferate in the pre-
sence of epidermal growth factor (EGF) and/or fibro-
blast growth factor 2 (FGF2) [4,5]. Neurospheres have
been demonstrated valuable for a number of approaches
[6,7]. They have also been used in a screening applica-
tion, searching for growth inhibitors [8] however some
of the characteristics of the neurospheres culture make
them not the elective method for screening applications.
In fact, their composition is highly heterogeneous being
the growing cell population characterized by progenitor
cells, astroblasts, neuroblasts and differentiated progeny
[9].
A possible source of interesting stem cells for drug
screening studies is represented by the Embryonic Stem
Cells (ESC). These cells allow the obtainment of transi-
ent populations of progenitors that divide in vitro and
t h a tc a nb et h e nd i f f e r e n t i a ted into a large number of
different cell types [10]. Desbordes et al [11] have suc-
ceeded in the attempt to apply human ESCs (hESCs) to
high-throughput screening (HTS) assays conducted in
384-well microplates. By employing the pluripotency
factor Oct4 as a primary read-out for hESCs differentia-
tion combined with a fully automated high-throughput
laser-scanning confocal microscopy screening, a number
of chemical compounds have been identified for their
ability to influence hESCs maturation. However, as the
authors themselves highlight, hESCs will become suita-
ble for routine HTS applications only when the variabil-
ity in the quality of hESCs maintained in bulk cultures
will be overcome [12].
Our work focused on the characterization and imple-
mentation of a mouse derived NS cells system which
can be long-term propagated in the absence of
unwanted differentiation. NS cells grow homogeneously
in monolayer and show a high potential to give rise to
functionally mature neurons even after long term expan-
sion, which may be exploited for screening applications.
These cells can be generated from mouse embryonic
stem cells (mES) or from fetal and adult nervous tissues
[13,15], as well as derived from human fetal brain tis-
sues [13,16]. NS-like cells capable of growing in mono-
layer have been recently obtained also from hESCs [17].
NS cells undergo sustained symmetrical self renewal in
response to FGF2 and EGF, independently from any
specific cellular niche [13]. Moreover, they display char-
acteristics of neurogenic radial glia, since they are
immunopositive for Nestin, RC2, Pax6, Vimentin, BLBP
and GLAST and show interkinetic nuclear migration, a
feature of neuroepithelial and radial glia cells in vivo
[13]. Importantly, these stem cells are able to generate
neurons, glial cells and oligodendrocytes and retain neu-
rogenic potential after extensive in vitro expansion
[13,18]. More recently, our group has developed a neu-
ronal differentiation protocol which gives rise to 80-85%
neurons from ES-derived NS cells, out of which
a p p r o x i m a t e l y7 0 %a r ef u n c t i o n a l l ya c t i v e[ 1 9 ] .W h e n
applied to NS cells derived from the adult Sub Ventricu-
lar Zone (SVZ) of the mouse, a modification of this pro-
tocol generates a cellular population of which 65% are
MAP2+ cells co-expressing GABA, GAD65/67, calbindin
and parvalbumin and generating action potentials after
21 days in vitro differentiation [15].
Here we demonstrate that it is possible to grow these
mouse NS cells in microplates and to monitor their pro-
liferation rate and propensity to cell death using homo-
genous assays. Moreover, we confirm the capacity of
adult SVZ-derived NS cells to undergo neuronal differ-
entiation in microplate culture conditions (96- and 384-
well microplates) without any reduction in the efficiency
with respect to what observed in 24-well dishes [15].
We also report the application of homogenous assays to
evaluate caspases 3/7 activity and cAMP levels in self-
renewing NS cells and mature neurons, both using fixed
and alive cells, with the incomparable advantage of
opening to the possibility of monitoring specific patho-
physiological parameters in well characterized stem cell-
derived neuronal populations.
Methods
Chemicals
Forskolin (Tocris#1099), H2O2 (Sigma Aldrich#H1009),
Ro 20-1724 (Sigma Aldrich #B8279), Staurosporine
(Sigma Aldrich#S4400).
IBMX (Sigma Aldrich#I7018), NECA (Tocris#1691),
CGS21680 (Tocris#1063), SCH58261 (Tocris#2270),
SKF 38393 (Sigma Aldrich#D-047), quinpirole (Sigma
Aldrich#Q-102), serotonine (Sigma Aldrich#H-9523),
buspirone (Tocris#0962), RS67506 (Tocris#0990), acetyl-
choline (Sigma Aldrich#A2661), GABA (Sigma
Aldrich#A5835).
Cell culture
The obtainment of LC1 cells, a mouse ESC-derived NS
cell line, is described in Conti et al, 2005 [13]. The adult
SVZ-derived NS cells line aNS-1 was derived from the
S V Zo fa2 - m o n t h s - o l dw i l d - t y p e( C D 1s t r a i n )m o u s e ,
as previously reported [14].
NS cells were routinely cultured on Iwaki plasticware
(Bibby, Italy) in NS proliferation medium, composed by
Euromed-N medium (Euroclone) supplemented with N2
supplement (Gibco, Invitrogen, Italy), 10 ng/ml EGF
(Peprotech Inc.) and 10 ng/ml FGF-2 (Peprotech Inc.).
Detailed protocols for routine handling of aNS-1 cells
are available elsewhere [14,15].
Differentiation of NS cells
LC1 cells were differentiated using an optimized proto-
col in serum-free conditions [19]. Briefly, proliferating
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then plated on untreated plastic dishes in Euromed-N
medium (EuroClone) medium supplemented with 5
mg/mL penicillin/streptomycin (Gibco, Invitrogen), 5
mg/mL L-Glutamine (Gibco, Invitrogen), 1% B27
( G i b c o ,I n v i t r o g e n ) ,0 . 5 %N 2( G i b c o ,I n v i t r o g e n )a n d
10 ng/ml FGF2 (Peprotech, Tebu-Bio). After 3 days at
37°C cultures were dissociated with Accutase and cells
were plated onto laminin-coated dishes in 1/4 DMEM
F12 (Invitrogen) medium plus 3/4 Neurobasal (Invitro-
gen) supplemented with 5 mg/mL penicillin/streptomy-
cin, 5 mg/mL L-Glutamine, 1% B27, 0.5% N2, 10 ng/
ml FGF2 and 20 ng/ml BDNF (Peprotech, Tebu-Bio)
for additional 3 days. Subsequently, for terminal differ-
entiation, the cultures were exposed to 1/4 DMEM
F12 medium plus 3/4 Neurobasal supplemented with 5
mg/mL penicillin/streptomycin, 5 mg/mL L-Glutamine,
1% B27, 0.5 % N2, 6.6 ng/ml FGF2 and 30 ng/ml
BDNF and kept in these conditions for additional 7-14
days. During this period medium was changed every 3
days.
For neuronal differentiation of aNS-1 cells, the specific
neuronal differentiation procedure was performed using
4 step-specific media which contain DMEM F12/Neuro-
Basal in specific ratios and definite supplements (D1-D4
media). The original detailed protocol is available else-
where [15].
For adaptation to microplate format, both LC1 and
aNS-1 cells were plated at a density of 30 × 10
3 cells/
well in 96-well microplates and 16 × 10
3 cells/well in
384-well microplates. The medium changes required for
the differentiation procedure were optimized so that
only half of the media present in the well was removed
and the same volume of fresh media was added. Fresh
media for media change contained a double amount of
growth factors in order to maintain the defined growth
factors concentration, considering a complete growth
factors depletion after 3 days in culture. Finally, to pre-
vent problems related to media evaporation, the wells
on the borders of the microplates were filled with Phos-
phate Buffered Saline (PBS) and not plated with cells
(this means that 60 wells were considered useful for
cell-plating in the 96-well microplates and 308 in the
384-well microplates).
Immunofluorescence
At the indicated time points, proliferating or differen-
tiated LC1 or aNS-1 cells were fixed by adding an
equal volume of 8% formaldehyde to the media con-
tained in the well. After 15 minutes at room tempera-
ture, cells were rinsed with PBS, permeabilized with
0.5% Triton X100-PBS for 15 minutes and incubated
for one hour in blocking solution (5% fetal calf serum
(FCS)-PBS or 2% BSA-PBS). Primary antibodies were
diluted in blocking solution and applied overnight at 4°
C. Primary antibodies used in this work are: anti beta
III-tubulin (1:1000; Promega); anti BLBP (1:1000; Che-
micon); anti cleaved caspase-3 (1:100; Cell Signaling);
anti GFAP (1:750; DAKO); anti MAP2 (1:500; Chemi-
con); anti Nestin (1:250; Chemicon); anti Olig2 (1:500;
Chemicon); anti Phospho Histone3 (1:100; Cell Signal-
ing); anti Vimentin (1:100; Developmental Studies
Hybridoma Bank). After three washes in PBS, appro-
priate secondary antibodies conjugated to Alexa fluoro-
phores 488 or 568 (Molecular Probes, Invitrogen) were
diluted at 1:500 in blocking solution in the presence of
DAPI (Sigma Aldrich#D9564, 1 mg/ml) to counterstain
the nuclei and applied for 2 hours at room tempera-
ture. The cells were then washed three times in PBS
buffer.
Images acquistion and analysis
The 20× images were acquired with a DMI3000 B
microscope (Leica) or BD Pathway Bioimager 855 (Bec-
ton Dickinson) as indicated. Attovision software has
been used for quantitative analysis.
Cell proliferation assays
aNS-1 cells were plated in proliferation medium in 96-
or 384-well microplates. cAMP-Glo Assay (Promega) or
MTT viability assay (Sigma Aldrich) were performed
starting one day after plating (0 h) every 24 hours (24 h,
48 h, 72 h).
Apoptotic assays
Apoptotic assays have been optimized on proliferating
LC1 cells and on differentiating aNS-1 cells. LC1 cells
were plated in 96-well microplates at the density of 12 ×
10
3 cells/well. The day after, NS expansion medium was
replaced with the same medium containing the desired
treatments. Caspase-Glo 3/7 Assay (Promega) was per-
formed 48 hours after the exposure to the different
treatments. Data were normalized using CellTiter-Blue
Cell Viability Assay (Promega).
aNS-1 derived neuron like cells were exposed to dif-
ferentiation medium containing the desired treatments.
After 24 hours Caspase-Glo 3/7 Assay (Promega) was
performed. Data were normalized using MTT Viability
Assay.
cAMP assay
aNS-1 derived neurons at the desired time after differ-
entiation were exposed to the following treatments and
concentrations in presence of phosphodiesterase inhibi-
tors IBMX 100 mM and Ro20-1724 100 mM: SKF
38393 5 mM, 0.5 mM, 0,110 mM; quinpirole 100 mM,
10 mM, 1 mM; serotonine 100 mM, 10 mM, 1 mM, 0.1
mM, 0.01 mM, 0.001 mM; buspirone 100 mM, 10 mM,
1 mM, 0.1 mM, 0.01 mM, 0.001 mM; RS67506 100
mM, 10 mM, 1 mM, 0.1 mM, 0.01 mM; acetylcholine
100 mM, 10 mM, 1 mM, 0.1 mM, 0.01 mM, 0.001 mM.
cAMP-Glo Assay (Promega) was then performed follow-
ing the manufacturer’s instructions.
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aNS-1 cells were transiently transfected with plasmid
pDS-YFP (H148Q, I152L, V163L) using the Mouse NSC
Nucleofector Kit (Amaxa) according to the manufac-
turer’s instructions and immediately plated in 96-well
microplates in differentiation medium. Yellow fluores-
cent protein (YFP) is an engineered variant of green
fluorescent protein, whose emission is quenched by
small anions. The protein used is a further variant of
YFP with three mutations, H148Q, I152L, V163S, each
of which greatly enhances YFP Cl
- sensitivity [20]. Cells
were differentiated for 21 days following the protocol
previously described. Fluorescence expression levels
were maintained at good levels during the differentiation
procedure and were monitored with BD Pathway Bioi-
mager 855 (Becton Dickinson) using a 20X objective (fil-
ter set for excitation at 500 ± 10 nm and emission 530
long pass emission filter). Immediately before the begin-
ning of the experiment the culture media in each well
was replaced with PBS (137 mM NaCl, 2.7 mM KCl, 0.7
mM CaCl2,1 . 1m MM g C l 2,1 . 5m MK H 2PO4,8 . 1m M
Na2HPO4, pH7.4). Cells were exposed to increasing con-
centration of NaCl (ranging from 0 mM to 400 mM) to
evaluate the effect of the extracellular Cl
- concentration
on the emitted fluorescence.
GABA (10 μM, 1 mM, 20 mM) was dissolved directly
in PBS and dispensed into each well using the injector
equipped on the BD Pathway Bioimager 855. Images
were acquired every 5 seconds after exposure to PBS
only, NaCl or GABA. All experiments were performed
at 37°C.
Statistical analysis
Where indicated, data have been evaluated by ANOVA
test.
Results
Adaptation of NS cells growth conditions to microplates
Mouse NS cells are regularly grown in 25 cm
2 flasks and
tested for their proliferation rate and differentiation cap-
ability in 24-well dishes. In these conditions, cells grow
stably and homogenously while maintaining their pluri-
potency and neurogenic capacity [15,19]. In order to
adapt their growth and differentiation potential to plate
formats compatible with high-throughput screening, we
have performed experiments in which seeding density
and medium volume per well have been optimized to
96- and 384-well formats. After harvesting, aNS-1 cells,
an adult SVZ-derived NS cell line [15], were plated at a
density of 4 × 10
3,8×1 0
3 or 16 × 10
3 cells/well in 96-
w e l la n da tad e n s i t yo f1×1 0
3,2×1 0
3 or 4 × 10
3
cells/well in 384-well microplates. 80 μla n d4 5μl
respectively of growth medium containing FGF and EGF
were added to the two formats. The day after plating
and for the following three days, cells did not show any
evident morphological change. After staining, they main-
tained expression of neural progenitor cell markers,
such as Nestin, Vimentin, BLBP and Olig2 (Figure 1A
and 1B). Analyses of Phospho Histone3 (P-H3) immu-
noreactivity shows that in both 96- and 384-well micro-
plates cells undergo self-renewal in absence of unwanted
differentiation as they do not express antigens proper of
neurons such as beta III-tubulin and MAP2, nor of glial
cells, such as GFAP (Figure 1A and 1B). Finally, the use
of 96- or 384-well microplates did not affect the survival
of the cells, as shown by the absence of active caspase-3
immunoreactivity (Figure 1A and 1B). Filling the wells
on the border of the microplates with PBS, allowed the
added media volume in each well to last for three days
after plating. These growth conditions in 96- and 384-
well formats have been successfully adapted also for
LC1, a NS cell line derived from ESCs [13] (Additional
file 1).
We conclude that mouse NS cells can be grown in
microplates in the absence of differentiation or
apoptosis.
aNS-1 efficiently generate neurons in microplates
Our recently developed protocols for an efficient genera-
tion of mature neurons from adult SVZ-derived and
ESCs-derived NS cells [16,20] were adapted to micro-
plates. We started by setting up parameters such as
seeding density and medium volume per well and
absence of evaporation. As we noticed that replacing the
entire medium was not appropriate for the cells we
adopted a partial medium change during differentiation
We firstly focused on aNS-1 cells and evaluated their
survival during the differentiation procedure in the dif-
ferent microplate formats. 40 × 10
3,3 0×1 0
3 and 20 ×
10
3 cells/well were plated in 96-well microplates and 16
×1 0
3 and 10 × 10
3 cells/well in 384-well microplates,
directly in 100 μl of D1 differentiation medium and ana-
lyzed after 3, 7, 14 or 21 days in vitro (DIV). At each
time point, 8 or 21 single wells from a 96- or 384-well
microplate, respectively, were fixed and nuclei stained
with DAPI. In order to obtain quantitative and objective
results, we used the BD Pathway Bioimager 855 and the
Attovision software. For each well, 16 fields chosen
through a geometric scheme independent from the
operator, have been scanned via the BD Pathway. The
single color images were then analyzed via the Attovi-
sion software, by using masks specifically designed to
discriminate signal intensity and signal shape, in order
to select functional nuclei and small picnotic nuclei.
The number of alive cells was then obtained by sub-
tracting the number of picnotic cells from the total cell
number. An exemplificative picture of the masks pro-
duced by the Attovision software to obtain the indicated
data is presented in Additional file 2. For each condi-
tion, an average of 4 × 10
3 cells/well were counted in
Garavaglia et al. BMC Neuroscience 2010, 11:7
http://www.biomedcentral.com/1471-2202/11/7
Page 4 of 15the 96-well. Average was 10 × 10
3 cells/well for 384-
wells. Six independent experiments have been carried
out in 96-wells and a single one in 384-well format.
Importantly, we found that after 21 days of differentia-
tion, which is the best timing for aNS-1 neuronal differ-
entiation [15], 75% of the initially plated cells were still
alive, both in the 96- and 384-well format (Figure 2A
and 2C, respectively; see Table 1 for detailed results).
We subsequently analyzed the maturation of the cells in
culture, by assessing the presence of specific antigens at
day 3, 7, 14 and 21. For this aim, an automated counting
procedure was adopted in a multiplexing acquisition
mode using a mask specifically designed on the peculiar
shape of differentiated aNS-1 cells. Three color-images
have been acquired from each selected field (DAPI to
stain nuclei, Alexa Fluor 488 for monoclonal Nestin and
beta III-tubulin, Alexa Fluor 546 for polyclonal GFAP
and MAP2) (Additional file 3) and analyzed via the
Attovision software. An average of 1700 and 700 cells
were counted in 96-well and in 384-well microplates,
respectively. As expected, three days after the beginning
of the differentiation procedure, the expression of
Figure 1 Adaptation of culture conditions of aNS-1 cells to microplates. aNS-1 cells can be cultured in 96- (A) and 384-well (B)p l a t e s ,
maintaining the expression of proper NS cells markers (Nestin, Vimentin, BLBP, Olig2), without exiting the cell cycle (Phospho-Histone3
immunoreactivity, P-H3), without differentiation (beta III-tubulin, MAP2 and GFAP absence) or cell death (cleaved caspase-3 absence).
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tained in this range during the entire differentiation pro-
cedure, with the same values being observed in 96- and
in 384-well microplates (Figure 2B and 2D). The immu-
nocytochemical analysis with antibodies against beta III-
tubulin and MAP2 shows the expected increase in the
number of immunoreactive cells with the majority of
them expressing beta III-tubulin and MAP2 at day 21 in
both microplate formats (Figure 2B and 2D). Finally, as
shown by GFAP immunoreactivity and subsequent ana-
lysis, the percentage of glial cells in these cultures is
very low (about 3-5%) (Figure 2B and 2D). Surprisingly,
this percentage obtained both in 96-well and 384-well
microplates is even lower than what originally observed
in the 24-well format [13,15]. The differentiation proce-
dure performed in microplates shows a strong well to
well reproducibility, as assessed by beta III-tubulin and
MAP2 expression in six independent wells from a 96-
well microplate (Additional file 4). Percentage of immu-
noreactive cells are also kept homogeneous among the
different wells at all time points (3, 7, 14 and 21 days of
differentiation). We also analyzed BrdU incorporation
along differentiation, confirming that NS cells gradually
stop proliferating during differentiation (DIV1: 28.39% ±
2.71, DIV7: 6.87 ± 0.85, DIV14: 0.79% ± 0.15). The best
results in terms of cell distribution in the well that led
to a density of differentiated aNS-1 cells suitable for
automated microscopy and image analysis from 3 to 21
days after plating, were obtained when plating 30 × 10
3
cells/well in 96-well and 16 × 10
3 cells/well in 384-well
microplates. At the time of analysis, nuclei were well
separated from each other and cells were distributed
evenly over the area of each well. Moreover, in this con-
dition, only a few overlapping nuclei are present, and we
were able to exclude them in the image analysis process
thanks to specifically designed masks. We also noticed
that a higher cell density is needed in these formats
with respect to the number of cells per well optimized
for 24 well plates (i.e. 50 × 10
3 cells/cm
2 in 24-well
plates vs 93 × 10
3 cells/cm
2 in 96- and 145 × 10
3 cells/
cm
2 in 384-well microplates). Under these conditions,
neuronal differentiation of NS cells in microplates is
robust and reproducible, as evident from Table 2 in
which 7 independent differentiation experiments per-
formed on aNS-1 cells at different in vitro passages are
presented. Moreover, in Table 3 it is possible to appreci-
ate a direct comparison between the differentiation effi-
ciency in 96- and 384-well microplates that highlights
the reproducibility of our differentiation procedure in
different plate formats. These data are in agreement
with the results obtained with the differentiation of
aNS-1 in standard 24-well plate format [15]. We con-
clude that we have successfully adapted the differentia-
tion of aNS-1 to microplates.
We next applied a similarp r o c e s sf o rL C 1c e l l s ,
adjusting to microplates the specific differentiation pro-
cedure of ESCs-derived NS cells, which differs from the
protocol used for aNS-1 cells because no replating of
the predifferentiated cells is necessary [19]. In this case
also, 30 × 10
3 cells were plated in 96-well and 16 × 10
3
cells in 384-well plates and a partial medium change
was applied during the differentiation process. The
images were acquired following the same stochastic
parameters used for aNS-1 cells and optimized masks
for differentiated LC1 cells morphology were developed.
Again results showed the expected decrease in Nestin
immunoreactivity, paralleled by an increase in beta III-
tubulin and MAP2 positive cells along the differentia-
tion. GFAP immunoreactivity was present at very low
levels at each analyzed time point (Additional file 5 and
data not shown).
So far, these results indicate that mature neurons
obtained from both aNS-1 and LC1 NS cells are suitable
for High-Content assays in a High-Throughput format.
Development of cell proliferation assays based on NS
cells
Based on the above evidence we set out to test NS cells
in high-content assays to measure their growth curve
and doubling time in 96- and 384-well microplates. We
first set the conditions for application of an ATP assay
(CellTiter Glo Luminescent Cell Viability Assay, Pro-
mega) on aNS-1 cells. A first series of experiments was
designed to test the impact on the proliferation rate of
different seeding densities of aNS-1 cells. We found that
for 96-well microplates the best condition was 8 × 10
3
cells/well; at this seeding density the doubling time of
N Sc e l l si sa b o u t3 1h( F i g u r e3 A ) ,a sp r e v i o u s l y
reported by our group [13] and the analysis of the cor-
relation coefficient revealed a R
2 = 0.9814. These results
represent the average data obtained from three indepen-
dent experiments. The intraplate reproducibility is also
appropriate, with a Coefficient of Variation (CV) of
0.0334 at 24 h and 0.0294 at 48 h when calculated
among 18 wells (Figure 3B). In 384-well microplates, the
best condition for an ATP assay is 4 × 10
3 cells/well,
with a doubling time of 34 h (Figure 3C; correlation
coefficient is R
2 = 0.9761 as calculated from three inde-
pendent experiments). The CV calculated among 18
wells is 0.0270 at 24 h and 0.0338 at 48 h. For results
obtained at the other tested densities, we invite the
reader to refer to Additional file 6.
We next tried to set up the MTT assay as an alterna-
tive assay for cell proliferation [21]. MTT assay applied
to NS cells in microplates presents a higher intraplate
variability (CV = 0.1977 after 24 h and CV = 0.0922
after 48 h of proliferation in 96-well formats) and a
lower correlation coefficient (R
2 = 0.9301) with respect
to the ATP assay. We therefore elected the ATP
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proliferating NS cells in microplates. Reproducible and
robust results have been obtained also by plating 12 ×
10
3 LC1 cells in 96-well and 4 × 10
3 cells in 384-well
formats (data not shown).
Application of cell death assays to self-renewing NS cells
The Caspase-Glo 3/7 Assay (Promega) is a homoge-
neous, luminescent assay that measures the activities of
caspase-3 and -7 enzymes, [22-24]. We used this assay
to monitor apoptotic cell death in proliferating LC1
cells. Therefore LC1 cells were first plated in 96-well
microplates and exposed to different doses of stauros-
porine, a well known proapoptotic molecule, ranging
from 200 to 1000 nM. After six hours of exposure to
this protein kinase inhibitor, we performed the Caspase-
Glo 3/7 Assay. As shown in Figure 3E, exposure of NS
cells to staurosporine causes a dose-dependent increase
in luciferase signal, paralleling the activation of caspases.
We subsequently tested the activation of caspases in
NS cells exposed to stress conditions. NS cells are iso-
lated and routinely expanded in the presence of EGF
and FGF2 [13]. Once a NS cell line is established, it is
possible to remove FGF2 and expand NS cells in the
presence of EGF only [14]. In fact, although FGF2 is
specifically required for initial derivation of NS cells,
addition of EGF is important for expansion of homoge-
nous NS cell cultures with efficient suppression of dif-
ferentiation and apoptosis. We plated LC1 cells in 96-
well plates in five different conditions, as described in
Figure 3F. After 48 hours, we performed the Caspase-
Glo 3/7 Assay. As shown in Figure 3F, removal of both
growth factors causes a dramatic activation of caspases
reaching 83 × 10
3 normalized RLU (Relative Luciferase
Figure 2 aNS-1 microplates differentiation procedure, quantitative results.( A) and (C): survival data during differentation in 96- (A) or 384-
(C) well plates. (B) and (D): immunocytochemical marker expression in 96- (B) or 384- (D) well plates. The graphs show the relative proportion
of alive cells expressing neural progenitor (Nestin), neuronal (beta III-tubulin, MAP2), and glial (GFAP) marker during differentation time. (A) and
(B) show mean ± SD from seven different experiments in 96-well microplates. (C) and (D) show mean ± SD from 21 different replicates in the
same experiment in 384-well microplates.
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Page 7 of 15Units) that are reduced to 31 × 10
3 normalized RLU in
the presence of 25% of the regular dose of FGF2. The
absence of EGF induces the activation of these enzymes,
b u ta tm u c hl o w e rl e v e l si fc o m p a r e dt ot h er e m o v a lo f
both growth factors (respectively 21 × 10
3 versus 83 ×
10
3 normalized RLU). Finally, the absence of FGF2 does
not evoke any increase in caspase activity; in fact the
level of caspases activation is similar to the value
obtained in standard culture conditions (11 × 10
3 versus
7×1 0
3 normalized RLU).
In conclusion, we have shown that it is possible to
measure the activation of specific apoptotic enzymes,
such as caspase-3 and -7, in NS cells plated in 96-well
microplates and exposed to a number of chemical
insults such as staurosporine or growth factor withdra-
wal, indicating that proliferating LC1 cells might be a
useful tool in the study of chemicals or molecules
impacting the apoptotic machinery.
aNS-1-derived neurons to investigate oxidative stress
Oxidative stress has long been linked to neuronal cell
death that is associated with certain neurodegenerative
conditions. Neurons are particularly prone to oxidative
stress and inadequately equipped with antioxidant
defense systems to prevent “ongoing” oxidative damage
[25]. As we moved to the optimization of homogenous
assays on neuronally differentiated NS cells we have
optimized the use of aNS-1 derived neurons as a tool
for the detection of hydrogen peroxide induced apopto-
sis. aNS-1 cells were plated in 96-well microplates and
exposed to the differentiation conditions. After three
days, cells were exposed to different doses of H2O2
(from 31.25 to 1000 mM) or staurosporine 0.01 mM as
positive control and the Caspase-Glo 3/7 Assay (Pro-
mega) was performed at the indicated time points. Data
were normalized on viability data as assessed by MTT
assay, which is more sensitive than ATP assay on differ-
entiated aNS1-cells (data not shown). We observed that,
as expected, after 6 h of exposure, staurosporine induces
a statistically significant activation of caspases (data not
shown). After 24 h, 1 mM and 500 μMH 2O2 cause a
statistically significant and dose-dependent activation of
caspases (Figure 4A). Furthermore, while the control
group showed the expected neuronal morphology and
dendritic networks, incubation with 250 mM, 500 mM
or 1 M H2O2 for 24 h caused a proportional decrease in
the number of viable cells (data not shown).
aNS-1 as a tool for screening of drugs/molecules able to
modulate cAMP levels
Neurons derived from aNS-1 cells have been tested for
their suitability in the evaluation of G-protein coupled
receptors (GCPRs) activity. The cAMP-Glo Assay (Pro-
mega) is a homogenous, non-radioactive assay, which
we have optimized for the use on differentiated aNS-1
cells in 96-well microplates. In these experiments, For-
skolin, a cell-permeable direct activator of Adenylate
cyclase, was taken as a reference compound for assay
validation. Exposure of aNS-1 cells to Forskolin 250
mM for 15 minutes at day 21 of differentiation, gives
rise to the expected statistically significant increase in
cAMP production (- 45% of luminescence signal, Figure
4B). The intraplate dispersion in the 96-well microplates
was assessed in 19 separate wells treated with Forskolin
250 mM versus 19 untreated wells. In both conditions
the observed spread of the data is satisfactory for the
purpose (Figure 4B). Moreover, the assay has been vali-
dated on aNS-1 cells differentiated for 3, 7 and 14 days
and the results overlap with those obtained at day 21 (-
3 5 %a t3d a y s ,-3 5 %a t7d a y sa n d-4 0 %a t1 4d a y s
with respect to untreated samples).
Subsequently, at day 21, aNS-1 cells have been
exposed to a panel of known agonists and antagonists of
GPCRs coupled receptor. Considering the Adenosine
receptor system, three agonists/antagonists have been
assessed per se or in combination: namely NECA (A1,
A2a, A3 agonist; 0.1 mM, 1 mM, 100 mM), CGS21680
(A2a agonist; 1 mM, 100 mM) and SCH58261 (A2a
antagonist; 10 mM).
Table 1 aNS-1 cell culture survival during differentiation
in 96-well microplates
Exp # Passage # Alive cell (%)
DIV3 1
2
2’
4
5
7
18
23
23
32
32
39
81.92 ± 2.86 (n = 3783)
81.29 ± 4.55 (n = 4017)
86.38 ± 2.58 (n = 10425)
n.a.
n.a.
87.20 ± 1.71 (n = 5158)
DIV7 1
2
2’
4
5
7
18
23
23
32
32
39
75.61 ± 2.80 (n = 5166)
74.01 ± 1.05 (n = 4394)
84.28 ± 3.74 (n = 11681)
76.40 ± 2.12 (n = 4457)
81.82 ± 1.38 (n = 4531)
85.70 ± 2.40 (n = 7310)
DIV14 1
2
2’
4
5
7
18
23
23
32
32
39
75.41 ± 3.16 (n = 4000)
66.72 ± 11.79 (n = 3595)
76.67 ± 2.69 (n = 11441)
74.96 ± 1.43 (n = 3757)
71.51 ± 2.32 (n = 3526)
65.01 ± 3.28 (n = 4947)
DIV21 1
2
2’
4
5
7
18
23
23
32
32
39
66.81 ± 2.92 (n = 3423)
74.77 ± 5.32 (n = 3988)
74.91 ± 3.72 (n = 7433)
72.44 ± 3.47 (n = 4187)
66.55 ± 6.19 (n = 3503)
69.66 ± 3.38 (n = 5108)
Data were evaluated by Attovision software. Experiments 1, 2, 4, 5, 7 were
performed in 96-well microplates. Experiment 2’ was performed in 384-well
microplate. Experiment 2 and 2’ were run in parallel. aNS-1 cells were
maintained in vitro for the indicated number of passages (Passage #); n:
number of cells analyzed.
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Page 8 of 15aNS-1 cell cultures differentiated for 21 days and once
exposed to NECA 100 mM showed a statistically signifi-
cant decrease of cAMP levels (+ 40% with respect to
untreated samples, Figure 4C). Using the adenosine A2a
agonist CGS21680 or the adenosine A2a antagonist
SCH58261 in combination with NECA, we did not
observe variations in NECA mediated cAMP modulation
(Figure 4C). These observations led us to conclude that
A1/A3 adenosine receptors, but not A2a receptor, are
present and functional in aNS-1 cells which were differ-
entiated for 21 days. Similar results were obtained after
3, 7 and 14 days of differentiation. Under the same
experimental conditions we have also tested SKF 38393
(a D1 like agonist), quinpirole (a D2 like agonist),
Table 2 Relative proportion of aNS-1 cells expressing neural progenitor, neuronal and glial antigens during
differentiation in 96-well microplates
Exp # Passage # Nestin beta III-tubulin MAP2 GFAP
DIV3 1
2
3
4
5
6
7
18
23
25
32
32
33
39
0 (n = 3074)
6.06 ± 3.34 (n = 608)
n.a.
n.a.
n.a.
10.00 ± 1.60
1.90 ± 0.52 (n = 1805)
52.22 ± 3.10 (n = 3134)
57.12 ± 14.03 (n = 661)
n.a.
n.a.
n.a.
51.47 ± 10.63
60.93 ± 0.63 (n = 2990)
64.13 ± 9.63 (n = 3074)
63.80 ± 8.12 (n = 608)
n.a.
n.a.
n.a.
45.60 ± 17.26
74.35 ± 4.71 (n = 1805)
0.17 ± 0.08 (n = 3134)
0.55 ± 0.61 (n = 661)
n.a.
n.a.
n.a.
5.30 ± 2.55
0.09 ± 0.15 (n = 2990)
DIV7 1
2
3
4
5
6
7
18
23
25
32
32
33
39
0.4 ± 0.07 (n = 4711)
1.36 ± 1.05 (n = 659)
3.14 ± 1.61
8.58 ± 3.72 (n = 366)
4.50 ± 2.02 (n = 367)
n.a.
1.64 ± 0.37 (n = 3791)
54.26 ± 1.59 (n = 3639)
59.91 ± 16.55 (n = 695)
40.27 ± 6.79
65.40 ± 14.70 (n = 470)
69.58 ± 10.74 (n = 453)
n.a.
66.86 ± 3.97 (n = 3666)
61.06 ± 7.56 (n = 4711)
61.31 ± 7.59 (n = 659)
39.02 ± 1.62
72.62 ± 9.71 (n = 366)
63.98 ± 12.95 (n = 367)
n.a.
74.89 ± 1.68 (n = 3791)
6.61 ± 2.58 (n = 4711)
2.13 ± 1.36 (n = 695)
5.33 ± 2.19
6.81 ± 8.91 (n = 470)
11.96 ± 4.46 (n = 453)
n.a.
0.43 ± 0.23 (n = 3666)
DIV14 1
2
3
4
5
6
7
18
23
25
32
32
33
39
0.40 ± 0.28 (n = 4475)
30.36 ± 3.61 (n = 715)
2.75 ± 2.15
7.39 ± 4.36 (n = 361)
4.57 ± 2.81 (n = 428)
3.49 ± 1.67
0.61 ± 0.37 (n = 2383)
40.94 ± 4.28 (n = 3416)
59.45 ± 9.59 (n = 636)
57.45 ± 7.19
66.05 ± 20.84 (n = 346)
77.40 ± 15.95 (n = 413)
43.52 ± 4.19
82.57 ± 3.86 (n = 2584)
74.25 ± 17.00 (n = 4475)
87.29 ± 6.77 (n = 715)
61.35 ± 7.16
61.67 ± 12.06 (n = 361)
62.67 ± 13.52 (n = 428)
52.72 ± 2.42
75.35 ± 5.32 (n = 2383)
4.43 ± 1.82 (n = 3416)
4.94 ± 1.48 (n = 636)
13.45 ± 4.13
8.70 ± 5.87 (n = 346)
17.60 ± 8.73 (n = 413)
1.94 ± 1.86
4.63 ± 0.21 (n = 2584)
DIV21 1
2
3
4
5
6
7
18
23
25
32
32
33
39
0 (n = 2968)
5.36 ± 3.40 (n = 598)
3.00 ± 1.33
6.35 ± 3.13 (n = 457)
6.13 ± 3.86 (n = 466)
n.a.
0.6 ± 0.39 (n = 2537)
62.29 ± 3.23 (n = 2455)
68.38 ± 11.07 (n = 573)
56.72 ± 6.65
59.95 ± 11.36 (n = 381)
75.10 ± 13.99 (n = 395)
n.a.
79.89 ± 16.80 (n = 2571)
92.60 ± 7.59 (n = 2968)
90.80 ± 14.67 (n = 598)
70.04 ± 5.16
68.11 ± 17.83 (n = 457)
84.65 ± 14.04 (n = 466)
n.a.
68.90 ± 10.77 (n = 2537)
5.85 ± 0.25 (n = 2455)
7.70 ± 3.29 (n = 573)
5.10 ± 0.73
16.60 ± 5.08 (n = 381)
18.20 ± 7.02 (n = 395)
n.a.
10.33 ± 3.19 (n = 2571)
Data were evaluated by Attovision software analysing aNS-1 alive cells expressing neuronal (beta III-tubulin, MAP2), neural progenitor (Nestin) and glial (GFAP)
markers. Results were obtained from seven independent experiments performed by starting with aNS-1 cells maintained in vitro for the indicated number of
passages are shown. Each experiment was performed in 96-well microplates; plating density was 30 × 10
3 cells/well; n: number of cells analyzed.
Table 3 Relative proportion of aNS-1 cells expressing neural progenitor, neuronal and glial antigens during
differentiation in 96- and 384-well microplates
Plate format Nestin beta III-tubulin MAP2 GFAP
DIV3 96W
384W
6.06 ± 3.34 (n = 608)
5.51 ± 3.45 (n = 155)
57.12 ± 14.03 (n = 661)
58.16 ± 7.14 (n = 904)
63.80 ± 8.12 (n = 608)
69.49 ± 5.07 (n = 882)
0.55 ± 30.61 (n = 661)
0.10 ± 0.30 (n = 904)
DIV7 96W
384W
1.36 ± 1.05 (n = 659)
n.a.
59.91 ± 16.55 (n = 695)
58.35 ± 6.20 (n = 999)
61.31 ± 7.59 (n = 659)
66.82 ± 9.47 (n = 738)
2.13 ± 1.36 (n = 695)
1.30 ± 1.04 (n = 999)
DIV14 96W
384W
3.36 ± 3.61 (n = 715)
2.84 ± 1.05 (n = 788)
59.45 ± 9.59 (n = 636)
62.54 ± 22.95 (n = 763)
87.29 ± 6.77 (n = 715)
71.53 ±19.17 (n = 788)
4.94 ± 1.48 (n = 636)
5.82 ± 2.65 (n = 763)
DIV21 96W
384W
5.36 ± 3.40 (n = 598)
6.00 ± 4.76 (n = 447)
68.38 ± 11.07 (n = 573)
80.89 ± 14.57 (n = 484)
90.80 ± 14.67 (n = 598)
98.76 ± 16.00 (n = 333)
7.70 ± 3.29 (n = 573)
9.22 ± 2.49 (n = 484)
Data were evaluated by Attovision software analysing aNS-1 alive cells expressing neuronal (beta III-tubulin, MAP2), neural progenitor (Nestin) and glial (GFAP)
markers; 96- and 384-well microplates experiments were run in parallel; n: number of cells analyzed.
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Page 9 of 15serotonine and buspirone (5-HT1A agonists), RS67506 (a
5-HT4 agonist) and acetylcholine for their ability to
influence GPCRs. However, none of these stimuli at the
doses indicated in the method section gave rise to a sta-
tistically significant modulation of cAMP levels (data
not shown).
aNS-1-derived YFP* reporter neurons as a tool to screen
for molecules active on GABA-A receptor
We next tested the validity of NS-derived neurons in
High-Content functional assays. In particular, we
focused on the evaluation of the GABA-A receptor, pre-
viously shown to be expressed and functionally active in
neurons derived from aNS-1 cells [15]. In order to eval-
uate the activity of this receptor, we have used a mutant
form of the YFP protein (YFP*), which is particularly
sensitive to anion levels variations [20]. Proliferating
aNS-1 cells were transiently transfected through the
nucleofection method (Amaxa) with the YFP* construct
and then exposed to differentiation procedure. After 21
days of differentiation in 96-well microplates, expression
of the exogenous fluorescent protein was still present
(Figure 5A, t = 0). After exposure of 21DIV aNS-1 cells
to 20 mM NaCl, a rapid decrease in the fluorescence
signal was observed (- 60% fluorescence intensity with
Figure 3 Cell proliferation and cell death assays.( A)a n d( C): Graphs of representative linear correlations in ATP assay performed in aNS-1
proliferating cells. 8 × 10
3 cells/well plated in 96-well microplates (A) and 4 × 10
3 cells/well plated in 384-well microplates (C); data are
expressed as growth (%), referred to the value obtained at t = 0. The data are the mean ± SD from three independent experiments, each one
performed in triplicate. (B) and (D): Data dispersion around mean value (full line) from ATP assays performed in 18 wells from a 96- (B) or a 384-
(D) well microplate; upper and lower groups represent 48 h and 24 h data respectively; letters in x axes identify each individual well; dot lines
represent 2SD from mean values. (E): Activation of Caspases 3/7 in LC1 cells exposed to the indicated doses of staurosporine for 6 hours. Data
are normalized on cell viability, as assessed by CellTiter-Blue Cell Viability Assay (F): Activation of Caspases 3/7 in LC1 cells exposed to the
indicated stress conditions for 48 hours. Data are normalized on cell viability. RLU: Relative Luciferase Unit.
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Page 10 of 15Figure 4 Homogeneous assays in aNS-1 derived neurons.( A): 3DIV aNS-1 differentiated cells were exposed to H2O2 or STS in 96-well
microplates for 24 h. Caspase 3/7 activation, normalized on vitality data as assessed by MTT assay, is reported. Results from one experiment
performed in triplicate are shown. Three independent experiments give rise to overlapping results. (B): 21DIV aNS-1 differentiated cells were
exposed to Forskolin 250 μM for 15’ and cAMP-Glo Assay™ was then performed on 19 well from a 96-well microplate. Row data dispersion
around mean value (full line) is reported; upper and lower groups represent untreated control and treated well data respectively; dot lines
represent 2SD from mean values: letters in x axes identify each individual well. (C): 21DIV aNS-1 differentiated cells were exposed to adenosine
receptor agonist/antagonist for 1 h. Forskolin for 15’ was used as positive control. Graph shows cAMP levels modulation, average value from
three independent experiments performed in triplicate. * p < 0.05, ** p < 0.01. H2O2: Hydrogen Peroxide; cps, counts per second; STS:
staurosporine.
Garavaglia et al. BMC Neuroscience 2010, 11:7
http://www.biomedcentral.com/1471-2202/11/7
Page 11 of 15r e s p e c tt oP B So n l yt r e a t e dc e l l s ,F i g u r e5 A ,t=7s e c ;
Figure 5B), that was restored 2 minutes after replacing
the physiological Chloride concentration (Figure 5A, t =
120; Figure 5B), thus demonstrating YFP* Chloride sen-
sitivity in aNS-1 cells. We also show that differentiated
NS-YFP* cells are sensitive to GABA stimuli. In fact, a
decrease in the fluorescence signal is detected starting
10 seconds after exposure to GABA 1 mM in PBS. To
obtain quantitative results, images of the treated cells
were acquired by the BD Pathway Bioimager 855 (Bec-
ton Dickinson) every 5 seconds after exposure to GABA
or PBS only for a 30 minutes period. The acquired
images have then been analyzed by ImageJ software in
order to obtain the fluorescent signal intensity for each
positive cell over time. These data (fluorescent signal
intensity versus time of exposure to the stimuli) have
been reported in graph, and the area under the curve
(AUC) has been used as a parameter referred to the
response to GABA stimuli (Figure 5C). We report that
the average AUC measured for the 14 PBS treated cells
analyzed was 2660 ± 108, while on 13 cells exposed to 1
mM GABA the average AUC was 2399 ± 105, indicating
a statistically significant decrease in the fluorescent sig-
nal specifically due to GABA exposure (- 9.81%). This
evidence reinforces previous data showing GABA
responsiveness in NS derived neurons [15].
Discussion
The development of reliable and reproducible cell-based
assays is a major goal in the current panorama of drug
screening where the application of cellular systems
highly resembling specific physiological contexts is
strongly required. The obtainment of a large amount of
specialized cells is, however, not trivial when thinking of
subtype specific, non-proliferating cellular populations.
The potential offered by stem cells in this sector appears
enormous thanks to their capability to self renew in
vitro and to produce interesting specialized phenotypes.
Stem cells may therefore be suitable for drug screening
application, in particular for the discovery of CNS-active
compounds, where primary cultures are more difficult
to obtain in the amounts required by HTS settings.
Here we report the adaptation of homogenous assays
and the development of High-Content assays in mouse
NS cells, an homogenous population of tissue-specific
stem cells that can be long-term propagated in the
absence of unwanted differentiation [13,14]. We thus
demonstrate that NS cells can be maintained in active
proliferation in 96- and 384-wells microplates and can
be adapted to homogeneous assays for the discovery of
molecules capable of activating and mobilizing endogen-
ous NS cells as well as for the identification of new
genes involved in the maintenance of the self renewal
state or in the differentiation processes. Being the
procedure to derive NS cells well defined [13,14], there
is the possibility to extend the application of the herein
validated homogeneous assays on NS cells obtained
from mice carrying genetic mutation of interest. More-
over it is also appealing to note that other neural stem
cell systems have been validated for their capability to
highlight the activity of compounds of interest. For
e x a m p l e ,i nt h ew o r kb yC h i o ue ta l .[ 2 6 ]P r o z a cw a s
demonstrated able to increase the cell viability and pro-
liferation of hippocampal derived neural stem cells and
to inhibit the production of proinflammatory cytokines
[26]. Validated and homogeneous neural stem cell sys-
tems are also needed as a basis for RNAi screens that
select for proteins that play crucial roles in stem cell
behavior. Furthermore, a specific interest in the avail-
ability of homogeneous neural stem cell systems arises
from the hypothesis that brain tumors are maintained
by rare cancer cells with stem cell-like properties [27].
Here we have adapted our optimized differentiation
protocol for NS cells [15] to 96- and 384-wells micro-
plates and developed homogeneous or High-Content
screenings through BD Pathway Bioimager 855 for the
evaluation of cell viability and differentiation efficiency
using a protocol that recapitulates different steps of neu-
ronal maturation. The automated analysis of several dif-
ferentiation trials also demonstrates that our microtiter
differentiation protocol is reproducible, robust and effi-
cient. The obtained differentiated cultures are rather
homogeneous for the expression of neuronal markers,
and the homogeneity of the culture is mandatory in a
HTS setting.
Experiments performed on aNS-1-derived YFP* repor-
ter neurons indicate that exogenous genes are main-
tained during the differentiation procedure, suggesting
that the engineering approach with a receptor of interest
is feasible. This is of particular interest given that cur-
rently, except for primary cells, there is no other neuro-
nal cell line available to monitor functionally active
neuronal-specific receptors. For example, although elec-
trophysiological studies have shown the presence of cur-
rents elicited by glutamate agonists in neuronally
differentiated NS cells [15], the same cells are not sensi-
tive to glutamate receptor activation. In fact, aNS-1 cells
differentiated in vitro for 21 days and exposed to gluta-
mate at the concentrations currently used in primary
cortical neurons to elicit cell death (ranging from 5 μM
to 10 mM) did not undergo cell death, as revealed by
LDH and ATP assay (data not shown). The engineering
approach pursued in NS cells may carry in the advan-
tage of a correct neuronal context in which to study the
receptor of interest, which is not present in the widely
used engineered immortalized cells,. Furthermore, the
possibility to use engineered NS cells differentiated in
microplate format allows the development of reporter
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Page 12 of 15Figure 5 An YFP based assay for the measurement of GABAA receptor activity.( A)a n d( B): Extracellular Cl- overload produces a rapid
decrease in cellular fluorescence that reaches the minimum in 7 sec. The fluorescence decrease is reversible, with complete recovery of resting
fluorescence occurring within 2 minutes after removal of extracellular Cl-. (C): 21DIV aNS-1 YFP* cells have been exposed to GABA 20 mM or PBS
only as a control. Fluorescence emission intensity has been recorded via AttoVision (BD Bioscience) every 5 seconds. Data elaboration through
the integration of the area under the curve shows a decrease of the fluorescence signals specifically in the cells exposed to GABA.
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Page 13 of 15based assays useful to monitor a specific cell fate. For
example, a random activation gene expression (RAGE)
approach [28] could be an option for the discovery of
new genes involved in the obtainment of a specific neu-
ronal population [29] and Albieri I, Onorati M, Calabr-
ese G, Moiana A, Badaloni A, Camnasio S,
Spiliotopoulos D, Cattaneo E, Consalez. GG: A DNA-
transposon-based approach to functional screening in
Neural Stem cells, submitted].
Conclusions
A thorough characterization of the available neural stem
cell systems is mandatory to understand their limits and
potential applications. Neurons from NS cells do not
replicate the full repertoire of neurochemical attributes
and functions that are present in primary neurons. Yet,
they offer the great advantage of being derived from
stable and replicating sources of stem cells which can be
maintained in monolayer and serum free conditions,
grown and efficiently differentiated in microtiter plates.
T h e s ep r o p e r t i e sm a k et h e ms u i t a b l ef o rH i g hC o n t e n t
and High throughput screening approaches searching
for compounds and new genes active in normal and dis-
eased neurons.
Additional file 1: Adaptation of culture conditions of LC1 cells to
microplates. LC1 cells can be cultured in 96-well plates, maintaining the
correct expression of NS cells markers (Nestin, Vimentin, BLBP, Olig2,
Phospho-Histone3), without differentiation (beta III-tubulin, MAP2 and
GFAP absence) or cell death (cleaved caspase-3 absence).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2202-11-7-
S1.PDF]
Additional file 2: Examples of the masks designed by the Attovision
software. The single colour images, acquired by the BD pathway, were
analysed via Attovision software by using specifically designed masks. (A)
Example of the mask designed to count DAPI positive alive cells. (B)
Mask created to count the total number of cells. (C) Mask able to select
picnotic cells only.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2202-11-7-
S2.PDF]
Additional file 3: Differentiating aNS-1 cells progressively acquire
neuronal antigenic properties when plated in microplates.
Downregulation of NS cells markers such as Nestin (green) and
upregulation of neuronal markers beta III-tubulin (green) and MAP2 (red)
in aNS-1 cells between DIV3 and DIV21. Low levels of glial marker GFAP
(red) were observed at all DIV times. Nuclei were stained with DAPI (blue;
all panels).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2202-11-7-
S3.PDF]
Additional file 4: Intra experiment reproducibility of aNS-1
differentiation procedure. Graphs show relative proportion of alive cells
expressing neuronal markers in 6 independent wells from a same 96-well
microplate. (A): beta III-tubulin expression. (B): MAP2 expression. Full lines
represent mean values.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2202-11-7-
S4.PDF]
Additional file 5: Differentiation of LC1 cells in 96-well plates.
Immunofluorescence experiment showing the expression of markers
during the differentiation of LC1 cells in 96-well plates. Most of the
differentiating NS cells lose Nestin expression, acquiring a neuronal
phenotype (beta III-tubulin and MAP2 immunoreactivity) instead of
becoming glial cells (GFAP immunoreactivity).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2202-11-7-
S5.PDF]
Additional file 6: Cell proliferation assays in 96- and 384-well
microplates. (A)and (C)Graphs of representative linear correlations in
ATP assay performed in aNS-1 proliferating cells, 4 × 10
3 cells/well (A)
and 16 × 10
3 cells/well (C) plated in 96-well microplates; (A) and (C):
data are expressed as growth (%), referred to the value obtained at t = 0.
The data are the mean ± SD from three independent experiments, each
one performed in triplicate. (B) and (D): Data dispersion around mean
value (full line) from ATP assays performed in 18 wells from 1 × 10
3 (B)
or 2 × 10
3 (D) cell/well plated in 384-well microplates; upper and lower
groups represent 48 h and 24 h data respectively; letters in x axes
identify each individual well; dot lines represent 2SD from mean values.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2202-11-7-
S6.PDF]
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